AngioDynamics reported mixed fiscal 2025 Q1 results. The medical technology company has had some good news recently, though. AngioDynamics continues to expect modest growth for the full year.

The NanoKnife system employs non-thermal IRE ablation to destroy tumour cells while preserving surrounding anatomy.

Peer-reviewed findings demonstrate high disease control and quality-of-life preservation, supporting shift toward focal therapy in prostate treatment “The publication of the PRESERVE study in European ...

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, ...

AngioDynamics has announced it has received FDA clearance for a new peripherally inserted central catheter, according to a news release. The company’s BioFlo peripherally inserted central catheters ...

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options ...

Trowbridge announced, "Based on our first quarter performance and our expectations for the balance of the year, we now expect net sales to be in the range of $308 million to $313 million, raised from ...

A month has gone by since the last earnings report for AngioDynamics (ANGO). Shares have lost about 3.9% in that time frame, underperforming the S&P 500. Will the recent negative trend continue ...

AngioDynamics Inc (NASDAQ: ANGO) has reported a Q4 FY23 adjusted EPS of $0.02, in line with the consensus EPS higher than $0.01 a year ago. Q4 sales increased 4.7% Y/Y to $91.07 million, beating the ...

Shares of AngioDynamics (NASDAQ: ANGO) were crashing 17.1% lower as of 10:43 a.m. ET on Thursday. The steep sell-off came after the medical technology company announced its fiscal 2025 first-quarter ...